TWILIGHT: A Randomized Trial of Ticagrelor Monotherapy Versus Ticagrelor Plus Aspirin Beginning at 3 Months in High-risk Patients Undergoing Percutaneous Coronary Intervention
US Cardiology Review · 2020-05-15 · 14
DOI: 10.15420/usc.2019.02 ↗At a glance
Übersichtsarbeit in US Cardiology Review, published online on 2020-05-15. Written by Johny Nicolas and 2 co-authors. Institution: The Zena and Michael A Wiener Cardiovascular Institute, Icahn School of Medicine at Mount Sinai New York City, NY. Cited 7 times so far (Crossref); 26 references. The full text is freely available (open access, CC BY-NC 4.0).
Abstract (original language)
A P2Y12 inhibitor-based monotherapy after a short period of dual antiplatelet therapy is emerging as a plausible strategy to decrease bleeding events in high-risk patients receiving dual antiplatelet therapy after percutaneous coronary intervention. Ticagrelor With Aspirin or Alone in High-Risk Patients After Coronary Intervention (TWILIGHT), a randomized double-blind trial, tested this approach by dropping aspirin at 3 months and continuing with ticagrelor monotherapy for an additional 12 months. The study enrolled 9,006 patients, of whom 7,119 who tolerated 3 months of dual antiplatelet therapy were randomized after 3 months into two arms: ticagrelor plus placebo and ticagrelor plus aspirin. The primary endpoint of interest, Bleeding Academic Research Consortium type 2, 3, or 5 bleeding, occurred less frequently in the experimental arm (HR 0.56; 95% CI [0.45–0.68]; p
Subjects
Author keywords
Authors and institutions
- The Zena and Michael A Wiener Cardiovascular Institute, Icahn School of Medicine at Mount Sinai New York City, NY.
Cite
APA
Nicolas, J., Baber, U., & Mehran, R. (2020). TWILIGHT: A Randomized Trial of Ticagrelor Monotherapy Versus Ticagrelor Plus Aspirin Beginning at 3 Months in High-risk Patients Undergoing Percutaneous Coronary Intervention. US Cardiology Review, 14. https://doi.org/10.15420/usc.2019.02
Vancouver
Nicolas J, Baber U, Mehran R. TWILIGHT: A Randomized Trial of Ticagrelor Monotherapy Versus Ticagrelor Plus Aspirin Beginning at 3 Months in High-risk Patients Undergoing Percutaneous Coronary Intervention. US Cardiology Review. 2020;14. doi:10.15420/usc.2019.02
BibTeX
@article{Nicolas2020,
author = {Nicolas, Johny and Baber, Usman and Mehran, Roxana},
title = {TWILIGHT: A Randomized Trial of Ticagrelor Monotherapy Versus Ticagrelor Plus Aspirin Beginning at 3 Months in High-risk Patients Undergoing Percutaneous Coronary Intervention},
journal = {US Cardiology Review},
year = {2020},
volume = {14},
doi = {10.15420/usc.2019.02}
}
EUVIMED